What is AVANIR Pharmaceuticals Financial Strength?
AVANIR Pharmaceuticals has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
AVANIR Pharmaceuticals did not have earnings to cover the interest expense.
AVANIR Pharmaceuticals's debt to revenue ratio for the quarter that ended in Sep. 2014 was 0.00.
As of today, AVANIR Pharmaceuticals's Altman Z-Score is 57.06.
Competitive Comparison of AVANIR Pharmaceuticals's Financial Strength
For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVANIR Pharmaceuticals's Financial Strength Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where AVANIR Pharmaceuticals's Financial Strength falls into.
AVANIR Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
AVANIR Pharmaceuticals's Interest Expense for the
months ended in Sep. 2014 was €-0.50 Mil. Its Operating Income for the
months ended in Sep. 2014 was €-9.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was €0.00 Mil.
AVANIR Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2014 is
| AVANIR Pharmaceuticals did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
AVANIR Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Sep. 2014 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
AVANIR Pharmaceuticals has a Z-score of 57.06, indicating it is in Safe Zones. This implies the Z-Score is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVANIR Pharmaceuticals (FRA:AV2B) Business Description
Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
AVANIR Pharmaceuticals (FRA:AV2B) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AV2B has been successfully added to your